The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine
暂无分享,去创建一个
James P. Hughes | Geoff P. Garnett | G. Garnett | J. Hughes | L. Koutsky | Laura Koutsky | J. Hughes
[1] G. Garnett,et al. Public health paradoxes and the epidemiological impact of an HPV vaccine. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[2] J S Koopman,et al. Assessing HIV vaccine effects. , 1995, American journal of epidemiology.
[3] D. Jenkins,et al. Withdrawing low risk women from cervical screening programmes: mathematical modelling study. , 1999, BMJ.
[4] P. Kaye. Infectious diseases of humans: Dynamics and control , 1993 .
[5] Sally M. Blower,et al. Imperfect vaccines and herd immunity to HIV , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[6] D M Parkin,et al. Estimates of the worldwide frequency of sixteen major cancers in 1980 , 1988, International journal of cancer.
[7] V. Moreno,et al. Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference , 2001, Journal of clinical pathology.
[8] R. May,et al. Directly transmitted infections diseases: control by vaccination. , 1982, Science.
[9] N. Kiviat,et al. Concurrent and sequential acquisition of different genital human papillomavirus types. , 2000, The Journal of infectious diseases.
[10] D J Nokes,et al. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes , 1996, Epidemiology and Infection.
[11] R. Anderson,et al. Contact Tracing and the Estimation of Sexual Mixing Patterns: The Epidemiology of Gonococcal Infections , 1993, Sexually transmitted diseases.
[12] G. Garnett. The influence of behavioural heterogeneity on the population level effect of potential prophylactic human immunodeficiency virus type 1 vaccines , 1998 .
[13] J. Dillner,et al. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. , 1999, The Journal of general virology.
[14] D C McCrory,et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. , 2000, American journal of epidemiology.
[15] T. Bjørge,et al. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11 , 1999, International journal of cancer.
[16] M. Halloran,et al. Cost-effectiveness of a routine varicella vaccination program for US children. , 1994, JAMA.